Cyclophosphamide Treatment in Pediatric Rheumatology and Nephrology Practices

    March 2025 in “ Pediatric Rheumatology ”
    Deniz Gezgin Yıldırım, Emine Yılmaz Orulluoğlu, Çişem Yıldız, Ceyhun Açarı, Hatice Adıgüzel Dundar, Okan Akacı, Nurver Akıncı, Emil Aliyev, Bedriye Nuray Alpman, Özge Altuğ Gücenmez, Elif Arslanoğlu Aydın, Bahriye Atmış, Pınar Özge Avar-Aydın, Fatma Aydın, Özge Baba, Esra Bağlan, İlknur Bağrul, Kenan Barut, Özge Başaran, Umut Selda Bayrakçı, Nuran Belder, Burcu Bozkaya Yücel, Bahar Büyükkaragöz, Sengul Caglayan, Mustafa Çakan, Elif Çelikel, Ferhat Demir, Selcan Demir, Yasemin Demir Yiğit, Fatma Gül Demirkan, Nida Dinçel, Şeyda Doğantan, Zahide Ekici Tekin, Esra Genç, Fatih Haşlak, Rana İşgüder, Aslıhan Kara, Müşerref Kasap Cüceoğlu, Ümmüşen Kaya Akça, Hakan Kısaoğlu, Rabia Miray Kışla Ekinci, Zehra Kızıldağ, Tuba Kurt, Batuhan Küçükali, Emre Leventoğlu, Hülya Nalçacıoğlu, Gülçin Otar Yener, Semanur Özdel, Yeşim Özdemir, Sümeyra Özdemir Çiçek, Sule Pektas Leblebiciler, Erkin Serdaroğlu, Hafize Emine Sonmez, Emine Nur Sunar Yayla, Serra Sürmeli Döven, Sezgin Sahin, Seher Şener, Ayşe Tanatar, Merve Kutlar, Sema Nur Taşkın, Betül Tiryaki, Serife Tuncez, Serkan Türkuçar, Bahriye Uzun Kenan, Nurdan Yıldız, Kenan Yılmaz, Yılmaz Tabel, İsmail Dursun, Nur Canpolat, Sevgı Mır, Harun Peru, Rezan Topaloğlu, Metin Kaya Gürgöze, Ayşe Balat, Yelda Bilginer, Banu Acar, Betül Sözeri, Erbil Ünsal, Özgür Kasapçopur, Sevcan A. Bakkaloğlu
    Image
    Studysummary This study found that clinicians frequently prefer cyclophosphamide over rituximab for induction therapy of childhood-onset systemic lupus erythematosus and ANCA-associated vasculitis, following a high-dose regimen recommended by the NIH.
    Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
    This study compared the use of cyclophosphamide (CYC) and rituximab (RTX) in pediatric rheumatology and nephrology for treating systemic lupus erythematosus (SLE) and ANCA-associated vasculitis (AAV). Conducted with 87 clinicians, it found that CYC is preferred for induction therapy due to its established efficacy, despite side effects like cytopenia, nausea, liver toxicity, and hair loss. The study noted the common practice of administering CYC with uromitexan to prevent bladder toxicity and emphasized the need for pre-treatment evaluations. While newer treatments like RTX are emerging, CYC remains favored in severe cases, and the study suggests developing pediatric guidelines to improve clinician awareness and patient care.
    Discuss this study in the Community →